1) Druker BJ, Guilhot F, O'Brien S, et al. IRIS Study Group. Long-term benefits of imatinib for patients newly diagnosed with chronic myelogenous leukemia in chronic phase: The 5-year update from the IRIS study. J Clin Oncol. 2006; 24(18S): 338s
|
|
|
2) Druker BJ, Guilhot F, O'Brien S, et al. Five-year folow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355: 2408-17
|
|
|
3) Feng W, Henk H, Thomas S, et al. Compliance and persistency with imatinib. J Clin Oncol. 2006; 24(18s): 310s
|
|
|
4) Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel of behalf of the European LeukeniaNet. Blood. 2006; 108: 1809
|
|
|
5) Mauro MJ, et al. Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res. 2006; 28(Suppl 1): S71-73
|
|
|
6) Cortes J, et al. Discontinuation of imatinib therapy after achieving a molecular response. Blood. 2004; 107: 2204
|
|
|
7) Merante S, et al. Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Hematologica. 2005; 90: 979-81
|
|
|
8) Rousselot P, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than two years. ASH annual meeting abstracts. 2005. 106a
|
|
|